Effects of Tislelizumab with Chemotherapy in Advanced Rectal Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of neoadjuvant Tislelizumab combined with chemotherapy in patients with locally advanced MSS rectal cancer. The approach involves administering 2 to 4 cycles of Tislelizumab alongside Oxaliplatin and Capecitabine, followed by total mesorectal excision surgery. The primary goal is to determine the proportion of patients achieving a pathological complete response (pCR) in their surgically resected tumors. This method aims to enhance immunogenic cell death while minimizing the toxic effects associated with standard treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years old and ≤70 years old.
* Pathologically diagnosed MSS ((confirmed by microsatellite stable detection or next-generation target sequencing) or (confirmed by immunohistochemistry)) colon adenocarcinoma.
* The lower edge of the tumor is less than 12cm from the anus as measured by colonoscopy and MRI,or TRUS.
* It was confirmed by magnetic resonance imaging (MRI) or intracavitary ultrasound of the rectum as T3-4 or N+, and M0 by enhanced CT.
* The ECOG physical status score is 0-1.
* Life expectancy is expected to be more than 1 year.
* First diagnosis, no previous anti-tumor treatment received, and no chemotherapy contraindications.
* Appropriate organ function is defined as follows: Hemoglobin level ≥ 90g/L, Neutrophil count ≥ 1.5×10\^9/L, Platelet count ≥ 75×10\^9/L, Serum total bilirubin ≤ 1.5× the upper limit of normal (UNL), Aspartate aminotransferase (AST) ≤ 2× UNL, Alanine aminotransferase (ALT) ≤ 3× UNL, Serum creatinine ≤ 1.5× UNL.
* Informed consent, able to understand the study protocol and willing to participate in the study, and will provide written informed consent.

Exclusion Criteria:

* Early rectal cancer (T1-2N0M0); The lower margin of the tumor was less than 5cm from the anus and T4. APR(combined abdominal perineal resection) is required;
* Multifocal colorectal cancer.
* Tumor obstruction or high risk of obstruction, bleeding, and/or perforation requiring emergency surgery or stent placement.
* Cannot tolerate chemotherapy or immunotherapy, such as but not limited to bone marrow suppression.
* History of malignant tumors, except for basal cell carcinoma, papillary thyroid carcinoma, and various in situ cancers.
* Acute exacerbation of important organ diseases (such as but not limited to COPD, coronary heart disease, and renal insufficiency) and/or severe acute infectious diseases (such as but not limited to hepatitis, pneumonia, and myocarditis), ASA score \> 3 points.
* Mental disorders, illiteracy, or language communication barriers that prevent the understanding of the study protocol.
* Peripheral sensory neuropathy, unable to receive oxaliplatin-based chemotherapy.
* Continuous use of glucocorticoids for more than 3 days within 1 month prior to signing the informed consent form, or having comorbidities requiring the use of glucocorticoid therapy.
* Unable to undergo enhanced CT examination
* Pregnancy or lactation.
* Refused to participate in this study.
* Other situations in which the researcher deems unsuitable for this study.

Where it's running

• The First Affiliated Hospital of Guangxi Medical University
  Nanning, Guangxi, China Recruiting

Study contacts

• Study coordinator: Sen Zhang, Professor
• Email: zs0771@126.com
• Phone: 13407738560

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Monitoring blood markers to predict treatment response in rectal cancer

  This study is testing if measuring certain blood markers in patients with stage II and III rectal cancer can help predict how well they respond to treatment.

  Recruiting Gene Solutions · Ho Chi Minh City · NCT06589388

• Prehabilitation program for patients with rectal cancer

  This study is testing a prehabilitation program to see if it helps people with rectal cancer feel better before surgery compared to standard care.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06565052

• Total neoadjuvant therapy with concurrent tislelizumab for low rectal cancer

  This trial tests whether adding the immunotherapy drug tislelizumab to total neoadjuvant chemotherapy helps adults with low rectal cancer reach a complete response so some can avoid major surgery.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT07561060

• Neoadjuvant mFOLFOX with Citrus Flavonoid Tablets for YWHAB-High Locally Advanced Rectal Cancer

  In people with locally advanced rectal cancer who have high YWHAB expression, this study tests whether adding citrus flavonoid tablets to a standard mFOLFOX neoadjuvant regimen helps shrink tumors before surgery.

  Recruiting Phase 2 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07176182

• Neoadjuvant chemoradiotherapy with or without tislelizumab for ultra-low rectal cancer – RELIEVE-02

  This study tests whether adding tislelizumab to standard chemoradiotherapy and subsequent chemotherapy improves anus preservation in adults with resectable ultra-low rectal cancer.

  Recruiting Phase 3 Fudan University · Shanghai · NCT07132463

• Neoadjuvant radiotherapy with toripalimab, liposomal irinotecan, and capecitabine for pMMR locally advanced low rectal cancer

  This trial will test whether adding toripalimab, liposomal irinotecan, and capecitabine to radiation before surgery helps adults with pMMR locally advanced low rectal cancer.

  Recruiting Phase 2 Affiliated Cancer Hospital of Shantou University Medical College · Shantou, Guangdong and 1 other locations · NCT07104604

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.